Co-Diagnostics (CODX) announced the development of a proprietary sample preparation instrument designed to streamline and simplify the workflow for its point-of-care Co-Dx PCR Mycobacterium Tuberculosis Test. The new instrument has been engineered to deliver a low-cost, user-friendly solution for sample processing in resource-limited PoC and near-PoC settings, supporting both sputum and the novel tongue swab sample collection used in the Company’s upcoming MTB test, which is expected to begin clinical evaluations in India before year-end. The single-button operation and no need for measurement or dispensing tools enable rapid sample prep with minimal training, while incorporating a built-in safety feature to inactivate live organisms in the sample and help protect test operators.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CODX:
- Co-Diagnostics to Present at Lytham Partners Conference
- Co-Diagnostics Announces $3.8M Securities Purchase Agreement
- Co-Diagnostics prices 9.62M shares at 40c in registered direct offering
- Co-Diagnostics signs MoU with partner in Kingdom of Saudi Arabia
- Co-Diagnostics performs in silico analysis of primers sets for chikungunya virus